Rezolute to Participate in Upcoming Investor Conferences
Rezolute (Nasdaq: RZLT), a late-stage rare disease company specializing in hypoglycemia treatment caused by hyperinsulinism, has announced its participation in three major upcoming investor conferences in September 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rezolute (Nasdaq: RZLT), a late-stage rare disease company specializing in hypoglycemia treatment caused by hyperinsulinism, has announced its participation in three major upcoming investor conferences in September 2025.
The company will attend the Cantor Global Healthcare Conference (September 3-5), the H.C. Wainwright Global Investment Conference (September 8-10), and the Morgan Stanley Global Healthcare Conference (September 8-10). Management will engage in Fireside Chats and one-on-one meetings with investors during these events.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences:
Event: Cantor Global Healthcare Conference
Date: September 3-5, 2025
Event: H.C. Wainwright 27th Annual Global Investment Conference
Date: September 8-10, 2025
Event: Morgan Stanley 23rd Annual Global Healthcare Conference
Date: September 8-10, 2025
Management will be participating in Fireside Chats and one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their Cantor, H.C. Wainwright, and Morgan Stanley representatives.
About Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (“HI”). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown meaningful benefit in clinical trials and real-world use for the treatment of congenital HI and tumor HI. For more information, visit www.rezolutebio.com.
Contact:
Rezolute, Inc.
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.